XML 51 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Cash Flows (USD $)
 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Cash flows from operating activities:    
Net loss $ (51,025,744) $ (27,728,736)
Loss from discontinued operations 27,260,584 792,113
Adjustments to reconcile net loss to net cash used in operating activities:    
Common stock, stock options and warrants issued as payment for compensation, services rendered and interest expense 5,471,166 8,164,814
Depreciation and amortization 1,160,596 1,221,346
Amortization of preferred stock discount and issuance cost 1,195,217 1,903,703
Changes in fair value of derivative liability (46,910) (1,661,049)
Write off of acquired in-process research and development 0 1,150,000
Loss on disposal of assets 12,964 0
Contributions paid with common stock 0 607,363
Bad debt expense (recovery) 328,003 59,538
Changes in operating assets and liabilities, net of the effect of acquisitions:    
Prepaid expenses and other current assets 4,337 (223,527)
Accounts receivable (1,112,107) (944,206)
Inventory 199,700 779,043
Unearned revenues (368,510) (159,900)
Other assets (187,123) 125,489
Accounts payable, accrued expenses and other current liabilities 711,997 (46,418)
Net cash used in operating activities - continuing operations (16,395,830) (15,960,427)
Net cash provided by (used in) operating activities - discontinued operations 12,168,199 (1,562,004)
Net cash used in operating activities (4,227,631) (17,522,431)
Cash flows from investing activities:    
Cash received in acquisitions 0 227,942
Cash received in divestiture 2,728,000 0
Change in restricted cash used as collateral for notes payable 0 (752)
Acquisition of property and equipment (197,577) (506,783)
Net cash used in investing activities - continuing operations 2,530,423 (279,593)
Net cash used in investing activities - discontinued operations (5,218,531) (2,848,309)
Net cash used in investing activities (2,688,108) (3,127,902)
Cash flows from financing activities:    
Net proceeds from exercise of options 0 7,100
Net proceeds from exercise of warrants 5,925,931 0
Net proceeds from issuance of capital stock 12,160,227 21,167,682
Repayment of mortgage loan (141,353) (109,492)
Proceeds from notes payable 223,433 149,766
Repayment of notes payable (187,956) (132,891)
Repayment of debt to related party 0 (3,000,000)
Repayment of preferred stock (2,258,852) (175,000)
Payment of dividend for preferred stock (56,850) 0
Payment for warrant inducement (43,716) 0
Net cash provided by financing activities - continuing operations 15,620,864 17,907,165
Net cash provided by financing activities - discontinued operations (5,198,330) (1,390,641)
Net cash provided by financing activities 10,422,534 16,516,524
Impact of changes of foreign exchange rates (72,136) 234,756
Net increase/(decrease) in cash and cash equivalents 3,434,659 (3,899,053)
Cash and cash equivalents at beginning of period 12,745,432 15,612,391
Cash and cash equivalents at end of period 16,180,091 11,713,338
Less cash and cash equivalents of discontinued operations at end of period 10,789,480 1,548,351
Cash and cash equivalents of continuing operations at end of period 5,390,611 10,164,987
Cash paid during the period for:    
Interest 1,655,600 1,238,400
Taxes 1,841,400 1,463,100
Supplemental Schedule of non-cash investing activities:    
Capitalized interest 154,700 235,700
Supplemental schedule of non-cash financing activities    
Common stock and warrants issued with the acquisition of PCT 0 17,200,000
Common stock issued pursuant to the redemption of Convertible Redeemable Series E 7% Preferred Stock 1,026,600 2,785,400
Common stock issued in payment of dividends for the Convertible Redeemable Series E 7% Preferred Stock 175,700 622,500
Dividend to related party reinvested as loan payable $ 0 $ 11,726,100